The overall objective of this study is to test an intervention of green tea extract (GTE) to mitigate neuropathic pain in patients, specifically cancer survivors, receiving supportive palliative care. The central hypothesis is that daily, oral, encapsulated GTE will mitigate neuropathic pain, as longitudinally measured by the validated Douleur Neuropathique 4 (DN4) and blood protein biomarkers reported to be linked to the development and/or chronicity of neuropathic pain.
18 years of age or older.
Established cancer-associated neuropathic pain.
A baseline Douler Neuropathique 4 (DN4) patient-reported neuropathic pain questionnaire score of greater than or equal to 4.
A stable pain management medication regimen, with no more than a 10% change in dosage in the past 14 days prior to enrollment.
Actively undergoing cancer treatment.
Symptoms and/or diagnosis of diabetic peripheral neuropathy.
Self-describe as consuming more than 3 cups of green tea or matcha beverages on a daily basis.
High probability of completing the study and all study-related measures/activities required by the protocol.
Parallel
Green Tea Leaf Extract Decaffeinated
Dietary supplementA purified green tea powder containing \~90% total polyphenols, more than 80% catechins (greater than or equal to 45% EGCG), and less than 1% caffeine.
Placebo Control
Other interventionRice flour
Change in neuropathic pain score
Douleur Neuropathique 4 (DN4) pain questionnaire. On a scale of 0 to 10, a score of equal to or greater than 4 equals neuropathic pain.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
